Efgartigimod efficacious, safe for primary immune thrombocytopenia
The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in The Lancet…
Read More
0
